Last reviewed · How we verify

Risperidone high dose — Competitive Intelligence Brief

Risperidone high dose (Risperidone high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry/Neurology.

marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Risperidone high dose (Risperidone high dose) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Risperidone high dose TARGET Risperidone high dose Johnson & Johnson Pharmaceutical Research & Development, L.L.C. marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Sertraline + Olanzapine Sertraline + Olanzapine Weill Medical College of Cornell University marketed SSRI + atypical antipsychotic combination Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT2A receptor
olanzapine therapy olanzapine therapy Eli Lilly and Company marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Intramuscular aripiprazole, olanzapine Intramuscular aripiprazole, olanzapine Veterans Medical Research Foundation marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Risperidone tablets Risperidone tablets Sumitomo Pharma (Suzhou) Co., Ltd. marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Aripiprazole; Quetiapine Aripiprazole; Quetiapine Taichung Veterans General Hospital marketed Atypical antipsychotic combination Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Standard of Care Oral antipsychotics Standard of Care Oral antipsychotics University of Utah marketed Antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Risperidone high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/risperidone-high-dose. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: